In the News

134 News Items found
Kenneth Offit and Vijai Joseph
Finding
An analysis of germline DNA in people with advanced cancer finds that inherited mutations may be more common than expected in this group.
MSK Surgeon Aimee Crago
In the Clinic
Surgeon and researcher Aimee Crago discusses the latest treatments for different types of soft tissue sarcoma, including liposarcoma and desmoid tumors.
MSK gastroenterologist Robin Mendelsohn seen smiling at desk.
Learn about the difference methods of colorectal cancer screening, including the at-home Cologuard test, from an expert at Memorial Sloan Kettering Cancer Center.
The largest, most comprehensive study of its kind from Memorial Sloan Kettering Cancer Center finds that the biology of colorectal cancer in people under 50 is very similar to the disease in older people and more aggressive treatment of younger patients may not be warranted.
Learn how exercise can help many people live longer after they are diagnosed with cancer, according to a new study from MSK's Exercise-Oncology Service.
Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to <i>U.S. News & World Report</i> in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. MSK was also ranked first in gynecology.
doctor and patients
In the Clinic
Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.
Illustration of a magnifying glass and DNA sequences
Finding
MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.
A women sitting in a chair holding a bell
Learn about some of the most important advances in cancer treatment at MSK in 2025.
Piro Lito, Bob Li, and Neal Rosen in the lab
In the Clinic
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.